Literature DB >> 9464505

Genomic structure of the human Smad3 gene and its infrequent alterations in colorectal cancers.

T Arai1, Y Akiyama, S Okabe, M Ando, M Endo, Y Yuasa.   

Abstract

The Smad3 gene is a member of the Smad family, vertebrate homologues of Drosophila Mad, and its gene product is a cytoplasmic element in the TGF-beta signaling pathway. Smad2 and Smad4/DPC4, other members of the Smad family, are possibly tumor suppressor genes because alterations of these genes occurred in various carcinomas. We determined the genomic structure of human Smad3 which consists of nine exons. Then we examined whether or not Smad3 gene mutations exist in sporadic and hereditary non-polyposis colorectal cancers and found no mutations in the entire coding region in 50 cancers. Loss of heterozygosity of Smad3 was observed in two of the 17 (11.8%) informative cases using a polymorphism found in intron 2. These findings suggest that the Smad3 gene may not play an important role in the tumorigenesis of colorectal cancers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9464505     DOI: 10.1016/s0304-3835(97)00384-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  11 in total

1.  Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction.

Authors:  M B Datto; J P Frederick; L Pan; A J Borton; Y Zhuang; X F Wang
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

2.  Gastric tumor development in Smad3-deficient mice initiates from forestomach/glandular transition zone along the lesser curvature.

Authors:  Ki Taek Nam; Ryan O'Neal; Yeo Song Lee; Yong Chan Lee; Robert J Coffey; James R Goldenring
Journal:  Lab Invest       Date:  2012-03-12       Impact factor: 5.662

3.  Mice exclusively expressing the short isoform of Smad2 develop normally and are viable and fertile.

Authors:  N Ray Dunn; Chad H Koonce; Dorian C Anderson; Ayesha Islam; Elizabeth K Bikoff; Elizabeth J Robertson
Journal:  Genes Dev       Date:  2005-01-01       Impact factor: 11.361

4.  Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta.

Authors:  X Yang; J J Letterio; R J Lechleider; L Chen; R Hayman; H Gu; A B Roberts; C Deng
Journal:  EMBO J       Date:  1999-03-01       Impact factor: 11.598

5.  Overexpression of FOXG1 contributes to TGF-beta resistance through inhibition of p21WAF1/CIP1 expression in ovarian cancer.

Authors:  D W Chan; V W S Liu; R M Y To; P M Chiu; W Y W Lee; K M Yao; A N Y Cheung; H Y S Ngan
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

6.  CTHRC1 is associated with peritoneal carcinomatosis in colorectal cancer: a new predictor for prognosis.

Authors:  Fei Tan; Feng Liu; Hao Liu; Yanfeng Hu; Dongning Liu; Guoxin Li
Journal:  Med Oncol       Date:  2013-01-29       Impact factor: 3.064

7.  Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.

Authors:  Wanglong Qiu; Frank Schönleben; Xiaojun Li; Gloria H Su
Journal:  Cancer Lett       Date:  2006-02-14       Impact factor: 8.679

Review 8.  Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta.

Authors:  N Dumont; C L Arteaga
Journal:  Breast Cancer Res       Date:  2000-02-21       Impact factor: 6.466

Review 9.  Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer.

Authors:  M Kretzschmar
Journal:  Breast Cancer Res       Date:  2000-02-21       Impact factor: 6.466

10.  Quantitative assessment of short amplicons in FFPE-derived long-chain RNA.

Authors:  Hui Kong; Mengou Zhu; Fengyun Cui; Shuyang Wang; Xue Gao; Shaohua Lu; Ying Wu; Hongguang Zhu
Journal:  Sci Rep       Date:  2014-11-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.